Oral lichen planus (OLP) is commonly found in middle-aged women. Although the cause is unknown, research points to several complex immunologic events and cells that are responsible for the inflammatory destruction and chronicity of these lesions. Biopsy for histologic diagnosis is recommended. The mainstay of treatment remains topical corticosteroids; however, newer therapies such as immunomodulating agents are available for recalcitrant lesions. In cases of lichenoid mucositis or reactions, treatment should be directed at identifying and removing the presumed cause. Given the apparent risk of squamous cell carcinoma in these patients, frequent follow-up and repeat biopsy are vital.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cden.2014.01.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Follicular porokeratosis (FPK) is a rare subtype of porokeratosis. Follicular porokeratosis mainly occurs in men and may be localized or diffuse. Involvement of the scalp is rarely reported, and we found only one case of alopecia due to scalp FPK.
View Article and Find Full Text PDFEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Molecular evidence for the efficacy of PBM therapy in the treatment of Oral lichen planus.
Photodiagnosis Photodyn Ther
January 2025
Department of Healthcare and Social Work, New Bulgarian University, Sofia, Bulgaria. Electronic address:
Purpose: Oral lichen planus (OLP) is a chronic inflammatory disease, in which T-Lymphocytes induce apoptosis of basal keratinocytes, leading to the formation of symptomatic lesions. It is assumed that blocking the cell death program and enhancing cell proliferation would be crucial to the healing process. The aim of the study was to verify the efficacy of Photobiomodulation (PBM) in OLP management, by evaluating the effects of laser irradiation on the processes of apoptosis and cell proliferation.
View Article and Find Full Text PDFThe Dermatologic Oral Examination: Navigating the Oral Dermatoses Map.
J Am Acad Dermatol
January 2025
Mayo Clinic Arizona, Department of Dermatology, Scottsdale, AZ, USA.
Traditionally, dermatological education emphasizes hair, skin and nails in its curriculum. There is a practice gap with regard to knowledge of normal oral mucosa variants, performance of the oral examination, and competence in diagnosing and treating oral mucosal disorders. The oral mucosa falls within the purview of dermatology.
View Article and Find Full Text PDFLichen planus (LP) is an autoimmune disease that may affect the oral cavity and the skin, and it has the potential to change to malignancy. In this paper we report a LP case in a 42-year-old male patient in which anxiety and depression were apparently the only possible risk factors of LP. Due to this apparent comorbidity and the risk of not responding well to conventional medication (topical and systemic corticosteroids) or the risk of relapse in the case of ongoing stress, we decided to integrate psychotherapy (without psychotropic drugs) as an adjunct into the management strategy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!